Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | MGAM | O43451 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SI | P14410 | 1/20 | 0.37 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.37 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30031260 | 0.84 | ALDH1A1 (0.39) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL10386529 | 0.84 | ALDH1A1 (0.39) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL21582004 | 0.83 | ALDH1A1 (0.37) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL22816036 | 0.81 | ALDH1A1 (0.36) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL10561417 | 0.80 | ALDH1A1 (0.39) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL18446 | 0.80 | ALDH1A1 (0.53) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL4132648 | 0.78 | ALDH1A1 (0.37) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL6842584 | 0.78 | ALDH1A1 (0.33) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL10388019 | 0.78 | CHRNB2 (0.33) | ALDH1A1MGAMGAASIMGAM2 | |
| SCHEMBL7138818 | 0.77 | ALOX15 (0.38) | ALDH1A1LMNAHSD17B10ALOX15MGAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118684667-A | Compounds for the treatment of fasciolopsis | 默克专利股份有限公司 | 2024-09-24 | — | — | CN | disclosed |
| CN-112512636-B | Compounds for the treatment of fasciolopsis | 默克专利股份有限公司 | 2024-06-18 | — | — | CN | disclosed |
| US-12006320-B2 | Heterocyclic derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2024-06-11 | — | — | US | disclosed |
| US-11744897-B2 | Folate receptor targeted nanoparticle drug conjugates and uses thereof | ELUCIDA ONCOLOGY, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230263899-A1 | FOLATE RECEPTOR TARGETED NANOPARTICLE DRUG CONJUGATES AND USES THEREOF | ELUCIDA ONCOLOGY, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230263898-A1 | FOLATE RECEPTOR TARGETED NANOPARTICLE DRUG CONJUGATES AND USES THEREOF | ELUCIDA ONCOLOGY, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230241243-A1 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | ELUCIDA ONCOLOGY, INC. | 2023-08-03 | — | — | US | disclosed |
| CN-115322199-A | Compounds and their use in the treatment of schistosomiasis | 默克专利股份有限公司 | 2022-11-11 | — | — | CN | disclosed |
| CN-110461848-B | Compounds and their use in the treatment of schistosomiasis | 默克专利股份有限公司 | 2022-09-20 | — | — | CN | disclosed |
| CN-108929281-B | Triazole compound and synthesis method and application thereof | 华东师范大学 | 2021-12-24 | — | — | CN | disclosed |
| EP-2227450-A2 | SELECTIVE ESTROGEN RECEPTOR MODULATOR COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASE | Oregon Health&Science University (US) | 2010-09-15 | — | — | EP | disclosed |
| US-20100152166-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | ELI LILLY AND COMPANY (US) | 2010-06-17 | — | — | US | disclosed |
| EP-2178851-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | Eli Lilly & Company (US) | 2010-04-28 | — | — | EP | disclosed |
| EP-2029558-B1 | COMPOUNDS AND METHODS FOR MODULATING FXR | LILLY CO ELI (US) | 2010-03-10 | — | — | EP | disclosed |
| US-20090124698-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATOR COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASE | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2009-05-14 | — | — | US | disclosed |
| WO-2009062082-A2 | SELECTIVE ESTROGEN RECEPTOR MODULATOR COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASE | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2009-05-14 | — | — | WO | disclosed |
| US-20090093524-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2009-04-09 | — | — | US | disclosed |
| EP-2029558-A2 | COMPOUNDS AND METHODS FOR MODULATING FXR | ELI LILLY AND COMPANY (US) | 2009-03-04 | — | — | EP | disclosed |
| WO-2009012125-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | ELI LILLY AND COMPANY (US) | 2009-01-22 | — | — | WO | disclosed |
| WO-2007140174-A2 | COMPOUNDS AND METHODS FOR MODULATING FXR | ELI LILLY AND COMPANY (US) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12006320-B2 | Heterocyclic derivatives as PI3K inhibitors | PIK3CD, PIK3R5, PIK3CA | ALDH1A1 2309/4885LMNA 3395/4885HSD17B10 1383/4885 |
| US-20230263899-A1 | FOLATE RECEPTOR TARGETED NANOPARTICLE DRUG CONJUGATES AND USES THEREOF | FOLR1, FOLR2, DHFR | ALDH1A1 1046/4885LMNA 3136/4885HSD17B10 3064/4885 |
| US-20090124698-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATOR COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASE | ESR1, GPER1, ESR2 | ALDH1A1 2898/4885LMNA 3942/4885HSD17B10 540/4885 |
| US-20230241243-A1 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | NDC1, KIFC1, SDCBP | ALDH1A1 1060/4885LMNA 605/4885HSD17B10 2628/4885 |
| US-20090093524-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | NR1H4, SLC10A1, FXR1 | ALDH1A1 2294/4885LMNA 2810/4885HSD17B10 104/4885 |
| US-20100152166-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | NR1H4, FXR1, SLC10A1 | ALDH1A1 2124/4885LMNA 2630/4885HSD17B10 117/4885 |
| US-20230263898-A1 | FOLATE RECEPTOR TARGETED NANOPARTICLE DRUG CONJUGATES AND USES THEREOF | FOLR1, FOLR2, DHFR | ALDH1A1 1046/4885LMNA 3136/4885HSD17B10 3064/4885 |
| US-11744897-B2 | Folate receptor targeted nanoparticle drug conjugates and uses thereof | FOLR1, FOLR2, DHFR | ALDH1A1 1046/4885LMNA 3136/4885HSD17B10 3064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.